40 Changes in prescription routines for treating hypothyroidism between 2001 and 2015 – a population-based study of 929,684 primary care patients in copenhagen

Bjarke Borregaard Medici, B. Nygaard, J. L. Cour, M. Grand, V. Siersma, D. Nicolaisdóttir, B. Lind, N. Olivarius, C. Andersen
{"title":"40 Changes in prescription routines for treating hypothyroidism between 2001 and 2015 – a population-based study of 929,684 primary care patients in copenhagen","authors":"Bjarke Borregaard Medici, B. Nygaard, J. L. Cour, M. Grand, V. Siersma, D. Nicolaisdóttir, B. Lind, N. Olivarius, C. Andersen","doi":"10.1136/bmjebm-2018-111070.40","DOIUrl":null,"url":null,"abstract":"Objectives Primary objective: To investigate changes in s-TSH threshold used by the general practitioners to initiate L-T4 therapy over the period 2001–2015 in Copenhagen. Method Primary objective Retrospective analysis of all s-TSH measurements between 2001 and 2015 performed at the general practitioners’ joint laboratory merged with The Danish Register of Medicinal Products Statistics and The Danish National Patient Registry. For each year in the period the estimated treatment threshold was calculated from the s-TSH measurements performed in that year as the level of s-TSH where the estimated probability of starting L-T4 therapy is 50%. Also the median level s-TSH at therapy initiation was recorded for each year. Results 929 684 individuals with 2 975 277 s-TSH measurements were included for the calculations. While the size and composition of the population serviced by the general practitioners remained virtually unchanged throughout the 15 year period, the number of performed s-TSH measurements increased from 110 886 in 2001 to 292 911 in 2015 and the number of patients initiating L-T4 therapy increased from 786 in 2001 to 1825 in 2015. The median s-TSH at L-T4 therapy initiation decreased from 10 mU/l (IQR 5.2–29.7) in 2001 to 6.8 mU/l (IQR 5.1–11) in 2015, while the estimated treatment threshold decreased considerably from 28.3 (95% CI 21.0 to 40.2) mU/l in 2001 to 14.2 (95% CI 12.0 to 18.0) in 2007 where it remained relatively unchanged for the rest of the study period. Conclusions This study performed on a sizeable primary care population demonstrates a considerable fall in the s-TSH threshold when initiating L-T4 therapy in hypothyroid patients, while the number of patients with s-TSH of 5–10 mU/l starting therapy increased considerably. Measuring TPO-antibodies appears to have influenced the s-TSH threshold considerably. The study also reveals that intensified TSH measuring from the 2010 level to the 2015 level did not lead to any further discoveries of hypothyroidism cases suggesting that very few hypothyroid persons remain undiagnosed.","PeriodicalId":298595,"journal":{"name":"BMJ Evidenced-Based Medicine","volume":"43 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Evidenced-Based Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjebm-2018-111070.40","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Objectives Primary objective: To investigate changes in s-TSH threshold used by the general practitioners to initiate L-T4 therapy over the period 2001–2015 in Copenhagen. Method Primary objective Retrospective analysis of all s-TSH measurements between 2001 and 2015 performed at the general practitioners’ joint laboratory merged with The Danish Register of Medicinal Products Statistics and The Danish National Patient Registry. For each year in the period the estimated treatment threshold was calculated from the s-TSH measurements performed in that year as the level of s-TSH where the estimated probability of starting L-T4 therapy is 50%. Also the median level s-TSH at therapy initiation was recorded for each year. Results 929 684 individuals with 2 975 277 s-TSH measurements were included for the calculations. While the size and composition of the population serviced by the general practitioners remained virtually unchanged throughout the 15 year period, the number of performed s-TSH measurements increased from 110 886 in 2001 to 292 911 in 2015 and the number of patients initiating L-T4 therapy increased from 786 in 2001 to 1825 in 2015. The median s-TSH at L-T4 therapy initiation decreased from 10 mU/l (IQR 5.2–29.7) in 2001 to 6.8 mU/l (IQR 5.1–11) in 2015, while the estimated treatment threshold decreased considerably from 28.3 (95% CI 21.0 to 40.2) mU/l in 2001 to 14.2 (95% CI 12.0 to 18.0) in 2007 where it remained relatively unchanged for the rest of the study period. Conclusions This study performed on a sizeable primary care population demonstrates a considerable fall in the s-TSH threshold when initiating L-T4 therapy in hypothyroid patients, while the number of patients with s-TSH of 5–10 mU/l starting therapy increased considerably. Measuring TPO-antibodies appears to have influenced the s-TSH threshold considerably. The study also reveals that intensified TSH measuring from the 2010 level to the 2015 level did not lead to any further discoveries of hypothyroidism cases suggesting that very few hypothyroid persons remain undiagnosed.
2001年至2015年间治疗甲状腺功能减退的处方常规变化——一项基于哥本哈根929,684名初级保健患者的人群研究
主要目的:调查2001-2015年哥本哈根全科医生开始L-T4治疗时s-TSH阈值的变化。方法主要目的回顾性分析2001年至2015年在全科医生联合实验室与丹麦药品统计注册和丹麦国家患者注册合并进行的所有s-TSH测量。在此期间的每一年,估计的治疗阈值是根据该年进行的s-TSH测量计算的,作为开始L-T4治疗的估计概率为50%的s-TSH水平。同时记录每年治疗开始时s-TSH的中位数水平。结果共纳入929684人,2 975 277 s-TSH测量值。虽然全科医生服务人群的规模和组成在15年期间几乎没有变化,但进行s-TSH测量的数量从2001年的110886例增加到2015年的292911例,开始L-T4治疗的患者数量从2001年的786例增加到2015年的1825例。l - t4治疗开始时的s-TSH中位数从2001年的10 mU/l (IQR 5.2-29.7)下降到2015年的6.8 mU/l (IQR 5.1-11),而估计的治疗阈值从2001年的28.3 mU/l (95% CI 21.0 - 40.2)下降到2007年的14.2 mU/l (95% CI 12.0 - 18.0),在研究期间的其余时间保持相对不变。本研究对相当大的初级保健人群进行了研究,结果表明,在甲状腺功能减退患者开始l - t4治疗时,s-TSH阈值显著下降,而开始治疗时s-TSH为5-10 mU/l的患者数量显著增加。测量tpo抗体似乎对s-TSH阈值有很大影响。该研究还表明,从2010年到2015年加强TSH测量并没有导致甲状腺功能减退的任何进一步发现,这表明很少有甲状腺功能减退患者未被诊断出来。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信